Acylcarnitines profile best predicts survival in horses with atypical myopathy.
Authors: Boemer François, Detilleux Johann, Cello Christophe, Amory Hélène, Marcillaud-Pitel Christel, Richard Eric, van Galen Gaby, van Loon Gunther, Lefère Laurence, Votion Dominique-Marie
Journal: PloS one
Summary
# Editorial Summary: Acylcarnitines as Prognostic Markers in Equine Atypical Myopathy Atypical myopathy (AM), triggered by hypoglycin A toxicity, carries a devastating prognosis with high mortality rates, yet clinical signs alone cannot reliably distinguish horses likely to survive from those that will not—creating a clinical dilemma around withdrawal of supportive care. Boemer and colleagues investigated whether the acylcarnitine metabolic profile, which directly reflects disturbances in muscle energy production during AM, could serve as an early prognostic tool by analysing serum samples from affected horses and developing a statistical prediction model. Three specific acylcarnitine species (C2, C10:2 and C18-carnitines) emerged as highly sensitive and specific predictors of survival outcome, demonstrating that these metabolic markers could distinguish survivors from non-survivors even amongst horses presenting with equally severe rhabdomyolysis. This finding has considerable clinical value: rather than relying on the severity of acute muscle damage signs to make difficult decisions about prognosis, practitioners can now order targeted metabolic profiling early in hospitalisation to identify which horses warrant intensive supportive therapy and which face insurmountable metabolic derangement. The ability to provide evidence-based prognostic guidance not only supports more humane decision-making but also optimises resource allocation and therapeutic focus during what remains a critical disease.
Read the full abstract on PubMed
Practical Takeaways
- •Request acylcarnitine profiling (specifically C2, C10:2, C18 levels) as an early prognostic tool in suspected atypical myopathy cases to guide euthanasia decisions and prioritize intensive care
- •Use this metabolic biomarker approach to distinguish horses with poor prognosis from those with survival potential, even when clinical signs appear equally severe across animals
- •This blood-based test provides objective prognostic data to support evidence-based decision-making in atypical myopathy management within the first hours of diagnosis
Key Findings
- •Three specific acylcarnitines (C2, C10:2, and C18) can be used to predict survival in horses with atypical myopathy with high sensitivity and specificity
- •Acylcarnitine profiles reflect muscle energetic derangement and can distinguish survivors from non-survivors early in disease course despite similar clinical severity
- •Prognostic estimation based on acylcarnitine profile allows early identification of horses unlikely to survive, preventing unnecessary suffering